Literature DB >> 13873036

Busulphan in the treatment of chronic granulocytic leukaemia.

J M BRIDGES, D M HAYES, M G NELSON.   

Abstract

Entities:  

Keywords:  BUSULFAN/therapy; LEUKEMIA/therapy

Mesh:

Substances:

Year:  1961        PMID: 13873036      PMCID: PMC2071163          DOI: 10.1038/bjc.1961.56

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  9 in total

1.  The treatment of chronic myeloid leukaemia with myleran.

Authors:  M G NELSON; J LOWRY
Journal:  Ir J Med Sci       Date:  1957-04       Impact factor: 1.568

2.  Myleran therapy in malignant neoplastic disease; use of 1,4-dimethanesulfonyloxbutane with emphasis on chronic granulocytic leukemia.

Authors:  G A HYMAN; A GELLHORN
Journal:  J Am Med Assoc       Date:  1956-06-30

3.  Medullary aplasia in chronic myeloid leukaemia during busulphan therapy.

Authors:  F G HAYHOE; D KOK
Journal:  Br Med J       Date:  1957-12-21

4.  Myleran in treatment of chronic myeloid leukaemia.

Authors:  E K BLACKBURN; G M KING; H T SWAN
Journal:  Br Med J       Date:  1956-04-14

5.  Treatment of chronic granulocytic leukemia with myleran.

Authors:  J LOUIS; L R LIMARZI; W R BEST
Journal:  AMA Arch Intern Med       Date:  1956-03

6.  Myleran in chronic myeloid leukaemia; chemical constitution and biological action.

Authors:  A HADDOW; G M TIMMIS
Journal:  Lancet       Date:  1953-01-31       Impact factor: 79.321

7.  Myelocytic leukemia: an analysis of incidence, distribution and fatality, 1910-1948.

Authors:  M B SHIMKIN; S R METTIER; H R BIERMAN
Journal:  Ann Intern Med       Date:  1951-07       Impact factor: 25.391

8.  The effect of alkylating agents on male rat fertility.

Authors:  H JACKSON; B W FOX; A W CRAIG
Journal:  Br J Pharmacol Chemother       Date:  1959-06

9.  Busulfan (1, 4-dimethanesulfonyloxybutane, myleran); summary of clinical results.

Authors:  D A GALTON; M TILL; E WILTSHAW
Journal:  Ann N Y Acad Sci       Date:  1958-04-24       Impact factor: 5.691

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.